A 804598 - CAS 1125758-85-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C19H17N5
Molecular Weight:
315.37
COA:
Inquire
Targets:
Others
Description:
A 804598 is a potent and competitive P2X7 receptor antagonist (IC50 = 8.9, 9.9 and 10.9 nM for mouse, rat and human P2X7 receptors, respectively).
Brife Description:
P2X7 receptor antagonist
Purity:
≥99% by HPLC
Synonyms:
N-Cyano-N"-[(1S)-1-phenylethyl]-N'-5-quinolinyl-guanidine; 1-cyano-2-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine
MSDS:
Inquire
InChIKey:
PQYCRDPLPKGSME-AWEZNQCLSA-N
InChI:
InChI=1S/C19H17N5/c1-14(15-7-3-2-4-8-15)23-19(22-13-20)24-18-11-5-10-17-16(18)9-6-12-21-17/h2-12,14H,1H3,(H2,22,23,24)/t14-/m0/s1
Canonical SMILES:
CC(C1=CC=CC=C1)N=C(NC#N)NC2=CC=CC3=C2C=CC=N3
1.[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.
Donnelly-Roberts DL;Namovic MT;Surber B;Vaidyanathan SX;Perez-Medrano A;Wang Y;Carroll WA;Jarvis MF Neuropharmacology. 2009 Jan;56(1):223-9. doi: 10.1016/j.neuropharm.2008.06.012. Epub 2008 Jun 17.
ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS. Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes. Data from gene knockout studies and recently described selective antagonists indicate a role for P2X7 receptor activation in inflammation and pain. While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors. A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors. A-804598 was tritiated ([3H]A-804598; 8.1Ci/mmol) and utilized to study recombinant rat P2X7 receptors expressed in 1321N1 cells. [3H]A-804598 labeled a single class of high affinity binding sites (Kd=2.4 nM and apparent Bmax=0.56 pmol/mg). No specific binding was observed in untransfected 1321N1 cells.
2.Isobolographic Analysis of Drug Combinations With Intrathecal BRL52537 (κ-Opioid Agonist), Pregabalin (Calcium Channel Modulator), AF 353 (P2X3 Receptor Antagonist), and A804598 (P2X7 Receptor Antagonist) in Neuropathic Rats.
Jung YH;Kim YO;Han JH;Kim YC;Yoon MH Anesth Analg. 2017 Aug;125(2):670-677. doi: 10.1213/ANE.0000000000001883.
BACKGROUND: ;Neuropathic pain should be treated with drug combinations exhibiting multiple analgesic mechanisms of action because the mechanism of neuropathic pain involves multiple physiological causes and is mediated by multiple pathways. In this study, we defined the pharmacological interaction of BRL52537 (κ-opioid agonist), pregabalin (calcium channel modulator), AF 353 (P2X3 receptor antagonist), and A804598 (P2X7 receptor antagonist).;METHODS: ;Animal models of neuropathic pain were established by spinal nerve ligation (SNL) in male Sprague-Dawley rats, and responses to the mechanical stimulation using von Frey filaments were measured. Drugs were administered by intrathecal route and were examined for antiallodynic effects, and drug interactions were evaluated using isobolographic analysis. The mRNA expression levels of pain-related receptors in each spinal cord or dorsal root ganglion of naïve, SNL, and drug-treated SNL rats were evaluated using real-time polymerase chain reaction.;RESULTS: ;Intrathecal BRL52537, pregabalin, AF 353, and A804598 produced antiallodynic effects in SNL rats. In the drug combination studies, intrathecal coadministration of BRL52537 with pregabalin or A804598 exhibited synergistic interactions, and other drugs combinations showed additivity.
3.ATP induces PAD4 in renal proximal tubule cells via P2X7 receptor activation to exacerbate ischemic AKI.
Rabadi M;Kim M;Li H;Han SJ;Choi Y;D'Agati V;Lee HT Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F293-F305. doi: 10.1152/ajprenal.00364.2017. Epub 2017 Oct 11.
We previously demonstrated that renal tubular peptidylarginine deiminase-4 (PAD4) is induced after ischemia-reperfusion (IR) injury and this induction of PAD4 exacerbates ischemic acute kidney injury (AKI) by promoting renal tubular inflammation and neutrophil infiltration. However, the mechanisms of renal tubular PAD4 induction after IR remain unknown. Here, we tested the hypothesis that ATP, a proinflammatory danger-associated molecular pattern (DAMP) ligand released from necrotic cells after IR injury, induces renal tubular PAD4 and exacerbates ischemic AKI via P2 purinergic receptor activation. ATP as well as ATPγS (a nonmetabolizable ATP analog) induced PAD4 mRNA, protein, and activity in human and mouse renal proximal tubule cells. Supporting the hypothesis that ATP induces renal tubular PAD4 via P2X7 receptor activation, A804598 (a selective P2X7 receptor antagonist) blocked the ATP-mediated induction of renal tubular PAD4 whereas BzATP (a selective P2X7 receptor agonist) mimicked the effects of ATP by inducing renal tubular PAD4 expression and activity. Moreover, ATP-mediated calcium influx in renal proximal tubule cells was blocked by A804598 and was mimicked by BzATP. P2X7 activation by BzATP also induced PAD4 expression and activity in mouse kidney in vivo.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 1922099-21-5 CCG 232601

CCG 232601
(CAS: 1922099-21-5)

CCG 232601 is a selective and orally bioactive inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 μM (SRE.L assay)) as a potential antifibrotic...

CAS 88416-50-6 Clodronate disodium tetrahydrate

Clodronate disodium tetrahydrate
(CAS: 88416-50-6)

Clodronate is a non-nitrogenous bisphosphonate that can bind to bone to reduce the bone resorption. It is used as an anti-osteoporotic drug for the prevention o...

CAS 131064-74-9 CGP-42454A

CGP-42454A
(CAS: 131064-74-9)

CGP-42454A is a epimer of Benazepril ,an approved drug using for the treatment of Hypertension.

MK 410
(CAS: 40738-05-4)

MK 410 is an anti-inflammatory drug which can induce alterations in the immune system by the suppression of plasma neutral proteinase activity.

CAS 145307-34-2 A 77636 hydrochloride

A 77636 hydrochloride
(CAS: 145307-34-2)

A 77636 hydrochloride is a potent and selective dopamine D1-like receptor agonist (pEC50 = 8.97 and < 5 for D1-like and D2-like receptors, respectively). A 7763...

CAS 1704740-52-2 AZ PFKFB3 26

AZ PFKFB3 26
(CAS: 1704740-52-2)

AZ PFKFB3 26 is a selective and potent metabolic kinase PFKFB3 inhibitor with IC50 value of 0.023 μM. It is selective for PFKFB3 over PFKFB1 and PFKFB2 isoforms...

CAS 55-86-7 Mechlorethamine hydrochloride

Mechlorethamine hydrochloride
(CAS: 55-86-7)

Mechlorethamine is the prototype of alkylating agents, it works by binding to DNA, crosslinking two strands and preventing cell duplication.

CAS 102767-28-2 Levetiracetam

Levetiracetam
(CAS: 102767-28-2)

Levetiracetam is an anticonvulsant medication used to treat epilepsy.

Chemical Structure

CAS 1125758-85-1 A 804598

Quick Inquiry

Verification code

Featured Items